Advanced Solid Tumor Clinical Trial
Official title:
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.
n/a
| NCT number | NCT05199753 |
| Study type | Interventional |
| Source | LaNova Medicines Limited |
| Contact | LaNova PM |
| Phone | +8615901815211 |
| [email protected] | |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Start date | March 16, 2022 |
| Completion date | June 2024 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
| Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
| Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04592653 -
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03704246 -
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04478461 -
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04999384 -
First in Human, Dose Escalation Study of AN4005
|
Phase 1 | |
| Recruiting |
NCT04375228 -
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
|
Phase 2 | |
| Active, not recruiting |
NCT04135261 -
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05071183 -
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01387321 -
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05021367 -
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Not yet recruiting |
NCT05051241 -
A Study of GFH018 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01453387 -
MSC2015103B in Solid Tumors
|
Phase 1 |